Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.59 |
| ▸ | STK4 | Q13043 | 2/20 | 0.49 |
| ▸ | STK3 | Q13188 | 2/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26953170 | 1.00 | LRRK2 (0.59) | LRRK2STK4STK3SGK1BRAF | |
| SCHEMBL31735012 | 0.87 | SGK1 (0.57) | LRRK2STK4STK3SGK1BRAF | |
| SCHEMBL26953278 | 0.87 | SGK1 (0.57) | LRRK2STK4STK3SGK1BRAF | |
| SCHEMBL31734890 | 0.86 | LRRK2 (0.59) | LRRK2STK4STK3SGK1 | |
| SCHEMBL26953245 | 0.86 | CDK2 (0.53) | LRRK2STK4STK3SGK1BRAF | |
| SCHEMBL31734958 | 0.86 | CDK2 (0.53) | LRRK2STK4STK3SGK1BRAF | |
| SCHEMBL26953145 | 0.86 | LRRK2 (0.59) | LRRK2STK4STK3SGK1 | |
| SCHEMBL31734861 | 0.83 | CYP2A6 (0.55) | LRRK2STK3SGK1JAK3CDK2 | |
| SCHEMBL31735009 | 0.83 | LRRK2 (0.52) | LRRK2STK4STK3SGK1BRAF | |
| SCHEMBL26953146 | 0.83 | LRRK2 (0.52) | LRRK2STK4STK3SGK1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | LRRK2 41/4885STK4 66/4885STK3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.